CYP-001 is under clinical development by Cynata Therapeutics and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect CYP-001’s likelihood of approval (LoA) and phase transition for Respiratory Failure took place on 01 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their CYP-001 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

CYP-001 overview

CYP-001 is under development for the treatment of steroid-resistant graft versus host disease, respiratory failure and acute respiratory distress syndrome associated with coronavirus disease 2019 (COVID-19). The therapeutic candidate is administered as an intravenous infusion. It is developed based on Cymerus platform stem cell technology.

Cynata Therapeutics overview

Cynata Therapeutics is a stem cell and regenerative medicine company. It develops and commercializes Cymerus, a stem cell platform technology used for the production of mesenchymal stem cells (MSCs) for human therapeutic use. Its proprietary technology platform utilizes induced pluripotent stem cells (iPSCs) originating from an adult donor for generating mesenchymoangioblasts (MCAs) in manufacturing the Cymerus MSC therapeutic products for the treatment of osteoarthritis, brain cancer and melanoma, Crohn’s disease, asthma, acute respiratory distress syndrome and heart attack. Its lead MSC product candidate CYP-001 is used for the prevention and treatment of Graft-versus-host-disease (GvHD). The company has operations in Ireland and, the US. Cynata Therapeutics is headquartered in Carlton, Australia.

Quick View CYP-001 LOA Data

Report Segments
  • Innovator
Drug Name
  • CYP-001
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Immunology
  • Infectious Disease
  • Respiratory
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.